Genetic and epigenetic analysis of the BAX and BCL2 in the placenta of pregnant women complicated by preeclampsia
- 165 Downloads
The current study examined the effects of BAX and BCL2 polymorphisms and methylation as well as mRNA expression on susceptibility to PE. After delivery, the placentas were collected from 92 women with PE, as well as 106 normotensive pregnant women. The BAX rs4645878 and BCL2 rs2279115 polymorphisms were genotyped by the PCR-RFLP method. Methylation-specific PCR (MSP) was used for analysis of promoter methylation. mRNA expression was assayed by Quantitative RT-PCR. In addition, in silico analysis was performed by bioinformatics tools. There was no relationship between PE and placental BAX rs4645878 and BCL2 rs2279115 polymorphisms. The groups were not significantly different regarding the promoter methylation of BAX gene. Nonetheless, the MM status of BCL2 promoter had a significantly higher frequency in the PE group and was associated with 2.7-fold higher risk of PE (OR = 2.7, 95% CI = 1.3–5.6; P = 0.01). The relative mRNA expression of BCL2 was decreased in the placentas of PE women (P < 0.0001). The expression of BAX gene was not significantly different between the two groups. There was no association between placental BAX rs4645878 and BCL2 rs2279115 polymorphisms and mRNA expression levels. In silico analysis indicated that BAX rs4645878 and BCL2 rs2279115 polymorphisms were located in the core recognition site of different transcription factors and these substitutions of wild allele resulted in the loss and/ or change of these binding sites and subsequently may alter BCL2 and BAX expression. This study showed that the BAX and BCL2 polymorphisms and BAX promoter methylation were not associated with PE risk. The BCL2 promoter methylation was associated with lower BCL2 expression and higher PE susceptibility.
KeywordsApoptosis Expression Methylation Preeclampsia Polymorphism
The study was supported by the Research Deputy in Zahedan University of Medical Sciences. We wish to acknowledge all the participants (patients and controls) in this research.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The Ethics Committee of Zahedan University of Medical Science approved study protocol (IR.zaums.REC.1396.44).
- 20.Liu ZH, Wang MH, Ren HJ et al (2014) Interleukin 7 signaling prevents apoptosis by regulating bcl-2 and bax via the p53 pathway in human non-small cell lung cancer cells. Int J Clin Exp Pathol 7:870–881Google Scholar
- 21.Ahani-Nahayati M, Solali S, Shams Asenjan K et al (2018) Promoter methylation status of survival-related genes in MOLT-4 cells co-cultured with bone marrow mesenchymal stem cells under hypoxic conditions. Cell J 20:188–194Google Scholar
- 29.Karimian M, Aftabi Y, Mazoochi T et al (2018) Survivin polymorphisms and susceptibility to prostate cancer: a genetic association study and an in silico analysis. EXCLI J 17:479–491Google Scholar
- 37.Mendilcioglu I, Karaveli S, Erdogan G, Simsek M, Taskin O, Ozekinci M (2011) Apoptosis and expression of Bcl-2, Bax, p53, caspase-3, and Fas, Fas ligand in placentas complicated by preeclampsia. Clin Exp Obstet Gynecol 38:38–42Google Scholar
- 38.Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA (2000) Placental apoptosis in preeclampsia. Obstet Gynecol 96:271–276Google Scholar
- 39.Yao Z, Yang B, Liu Z, Li W, He Q, Peng X (2017) Genetic polymorphisms of Bcl-2 promoter in cancer susceptibility and prognosis: a meta-analysis. Oncotarget 8:25270–25278Google Scholar
- 42.Lindner E, Glatz W, Schwab C, El-Shabrawi Y, Mossbock G (2015) Analysis of functional polymorphisms in apoptosis-related genes in primary open angle glaucoma. Mol Vis 21:1340–1344Google Scholar
- 47.Fernandes AT, Rocha NP, Vendrame E et al (2015) Polymorphism in apoptotic BAX (-248G> A) gene but not in anti-apoptotic BCL2 (-938C> A) gene and its protein and mRNA expression are associated with cervical intraepithelial neoplasia. Apoptosis: Int J Program Cell Death 20:1347–1357CrossRefGoogle Scholar